Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial.

The EMPA-REG study showed that treatment with empagliflozin significantly reduced all-cause and cardiovascular death and also showed a decreasing trend in the risk of sudden death [ 5 ].

also in 47,180 other papers

The placebo group showed a trend towards an increase in the number of total VPCs, single VPCs, double VPCs, and VTs per day recorded by Holter monitoring at post-treatment compared to pre-treatment (Table 2 ).

also in 53,322 other papers